Warfarin in atrial fibrillation patients with moderate chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 11, 2011, Pages 2599-2604

  Hart, Robert G ^a   Pearce, Lesly A ^b   Asinger, Richard W ^c   Herzog, Charles A ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Minot ^*  (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG EFFICACY; EMBOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STROKE;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BLOOD COAGULATION; CANADA; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 80655139710     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02400311     Document Type: Article

References (26)

1. Coresh J, Selvin E, Stevens LA: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
2. U.S. Renal Data System. USRDS 2009 annual data report. USRDS web site, www.usrds.org/reference. National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, Maryland.
3. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowksy L, Singer DE for the ATRIA Investigators: Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation. The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circ 199: 1363-1369, 2009
4. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146: 857-867, 2007
5. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20: 2223-2233, 2009
6. Chan KE, Lazarus JM, Thadhani R, Hakim RM: Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients. J Am Soc Nephrol 20: 872-881, 2009
7. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, Robinson BM: Atrial fibrillation in hemodialysis patients: Clinical features and associations with anticoagulant therapy. Kidney Int 77: 1098-1106, 2010
8. Marinigh R, Lane DA, Lip GYH: Severe renal impairment and stroke prevention in atrial fibrillation. J Am Coll Cardiol 57: 1339-1348, 2011
9. Stroke Prevention in Atrial Fibrillation Investigators: The Stroke Prevention in Atrial Fibrillation 3 Study: Rationale, design, and patient features. J Stroke Cerebrovasc Dis 5: 341-353, 1997
10. Stroke Prevention in Atrial Fibrillation Investigators: Adjusteddose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation 3 randomized clinical trial. Lancet 348: 633-638, 1996
11. Stroke Prevention in Atrial Fibrillation Investigators: Patients with nonvalvular atrial fibrillation at low-risk of stroke during treatment with aspirin: The Stroke Prevention in Atrial Fibrillation 3 Study: JAMA 279: 1273-1277, 1998
12. Landefeld CS, Anderson PA, Goodnough LT, Moir TW, Hom DL, Rosenblatt MW, Goldman L: The bleeding severity index: Validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 42: 711-718, 1989
13. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T Coresh J. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration: A new equation to estimate glomerular filtration rate Ann Intern Med 150: 604-612, 2009
14. National Kidney Foundation. K/DOQI Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Part 4. Definition and classification of stages of chronic kidney disease. Am J Kidney Dis 39[suppl 1]: S46-S57, 2002
15. Oden A, Fahlen M, Hart RG: Optimal INR for prevention of stroke and mortality in atrial fibrillation: A critical appraisal. Thrombosis Research 117: 493-499, 2006
16. Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, Go AS: Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? The ATRIA study. Circ Cardio-vasc Qual Outcomes 2: 297-304, 2009
17. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW: Factors associated with stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III trials. Stroke 30: 1223-1229, 1999
18. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: Results of the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870, 2001
19. Stroke Risk in Atrial Fibrillation Working Group: Independent predictors of stroke in patients with atrial fibrillation: A systematic review. Neurology 69: 546-554, 2007
20. Coresh J, Astor BC, McQuillan G, Kusek J, Greene T, Van Lente F, Levey AS: Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. Am J Kidney Dis 39: 920-929, 2002
21. Peake M, Whiting M: Measurement of serum creatinine-current status and future goals. Clin Biochem Rev 27: 173-184, 2006
22. Limdi NA, Beasley M, Baird MF, Goldstein JA, McGwin G, Arnett DK, Allon M: Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20: 912-921, 2009
23. ACTIVE Writing Group on behalf of the ACTIVE Investigators: Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): Randomised controlled trial. Lancet 367: 1903-1912, 2006
24. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly P, Themeles E, Varonne J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener H-C, Joyner CD, Wallentin L, and the RE-LY Steering Committee and Investigators:. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151, 2009
25. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Ta-lajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, San Tan R, Sim K-H, Lewis BS, Van Meighem W, Lip GYH, Hyung Kim J, Lanas-Zanetti F, Gonzalez-Her-mosillo A, Dans AL, Munawar M, O'Donnell M, Lawerence J, Lewis G, Afzal R, Yusuf S for the AVERROES Steering Com-mittee and Investigators: Apixaban in patients with atrial fi-brillation. N Engl J Med 364: 806-817, 2011
26. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976